Chief Executive Officer
Robert Greif is Chief Executive Officer and President of H-CYTE. Greif brings to H-CYTE a strong track record leading high-growth pharmaceutical and biotech businesses, having successfully taken more than a dozen products from discovery to commercialization.
“I am honored to be joining the H-CYTE team to innovate and implement novel growth strategies in our biologics development,” said Greif in a statement. “With a focus on evidence-based medicine, it is my hope for H-CYTE to immediately begin clinical research and development of a diverse pipeline of next-generation regenerative therapeutics to meet the needs of patients with a variety of diseases and chronic health conditions.”
Prior to joining H-CYTE, Greif was Chief Commercial Officer and Business Development Leader at Atox Bio, where he built the North American commercial organization in preparation for the launch of a first-in-class immunomodulator. Prior to that, he led the Commercial Operations of rEVO Biologics, an orphan disease biotechnology company. He has also held a variety of business unit and commercial leadership roles at United health Group, Boehringer Ingelheim and Sanofi SA.